智通财经网·2026-03-13 03:14Core Viewpoint - Rongchang Biopharma (09995) has seen its stock price increase by over 5%, currently trading at 90 HKD, following the acceptance of its RC288 injection application by NMPA, indicating strong market interest in its innovative drug pipeline [1] Group 1: Product Development - The RC288 injection, developed by Rongchang Biopharma, is a PSMA/B7H3 ADC that has demonstrated excellent anti-tumor activity and safety in preclinical studies [1] - The company is expected to enter a new growth phase starting in 2026, primarily driven by the launch of new indications for RC18, RC48, and RC28, which will also be included in medical insurance [1] Group 2: Future Revenue Streams - Sales from overseas indications for RC48 and RC18 are projected to begin in 2027, contributing to revenue through sales sharing agreements [1] - Starting in 2025, the company anticipates multiple asset licensing agreements, with upfront payments and milestones expected to enhance financial statements in the coming years [1] Group 3: Competitive Positioning - The newly entered global FIC pipeline, including CDCP1 ADC RC278 and B7H3/PSMA ADC RC288, holds potential global competitiveness and may lead to external licensing opportunities [1]